1 2	Neutralization of ancestral SARS-CoV-2 and variants Alpha, Beta, Gamma, Delta, Zeta and Omicron by mRNA vaccination and infection-derived immunity through homologous and
2	beterologous variants
5	
4	
5	Meriem Bekliz ¹ , Kenneth Adea ¹ , Pauline Vetter ^{2,3} , Christiane S Eberhardt ^{4,5,6} , Krisztina Hosszu-
6	Fellous ^{2,3} , Diem-Lan Vu ² , Olha Puhach ¹ , Manel Essaidi-Laziosi ¹ , Sophie Waldvogel-Abramowski ⁷ ,
7	Caroline Stephan ⁷ , Arnaud G. L'Huillier ⁸ , Claire-Anne Siegrist ⁴ , Arnaud M Didierlaurent ⁴ , Laurent
8	Kaiser ^{2,3} , Benjamin Meyer ^{4*} , Isabella Eckerle ^{1,2,3*}
9	
10	¹ Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland.
11 12	² Division of Infectious Diseases, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 6, Geneva 1205, Switzerland.
13	³ Geneva Centre for Emerging Viral Diseases, Geneva, University Hospital and Faculty of Medicine,
14	Geneva, Switzerland.
15	⁴ Center for Vaccinology and Neonatal Immunology, Department of Pathology and Immunology,
16	University of Geneva, Switzerland
17	⁵ Division of General Pediatrics, Department of Woman, Child and Adolescent Medicine, Faculty of
18	Medicine, University of Geneva
19	6Center for Vaccinology, Geneva University Hospitals, Geneva, Switzerland
20	⁷ Transfusion Unit, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland.
21	⁸ Pediatric Infectious Diseases Unit, Department of Women, Child and Adolescent Medicine, Geneva
22	University Hospitals and Faculty of Medicine, Geneva, Switzerland.
23	
24	*Corresponding authors:
25	Isabella Eckerle,
26	Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland.
27	Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, Switzerland.
28	Tel: +41223729820;
29	Email: isabella.eckerle@hcuge.ch
30	
31	Benjamin Meyer
32	Center for Vaccinology, Department of Pathology and Immunology, University of Geneva, Switzerland.
33	Rue Michel-Servet 1, 1211 Geneva 4, Switzerland
54 2⊑	iei. +4 i 22 3/9.5/.80
55	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

36 Abstract

- 37 Emerging SARS-CoV-2 variants of concern/interest (VOC/VOI) raise questions about effectiveness of
- 38 neutralizing antibodies derived from infection or vaccination. As the population immunity to SARS-CoV-
- 39 2 has become more complex due to prior infection and/or vaccination, understanding the antigenic

40 relationship between variants is needed.

Here, we have assessed in total 104 blood specimens from convalescent individuals after infection with
early-pandemic SARS-CoV-2 (pre-VOC) or with Alpha, Beta, Gamma or Delta, post-vaccination after

43 double-dose mRNA-vaccination and break through infections due to Delta or Omicron. Neutralization

44 against seven authentic SARS-CoV-2 isolates (B.1, Alpha, Beta, Gamma, Delta, Zeta, Omicron) was

- 45 assessed by plaque-reduction neutralization assay.
- 46 We found highest neutralization titers against the homologous (previously infecting) variant, with lower

47 neutralization efficiency against heterologous variants. Significant loss of neutralization for Omicron was
48 observed but to a varying degree depending on previously infecting variant (23.0-fold in Beta-

49 convalescence up to 56.1-fold in Alpha-convalescence), suggesting that infection-derived immunity

50 varies, but independent of the infecting variant is only poorly protective against Omicron. Of note, Zeta

51 VOI showed also pronounced escape from neutralization of up to 28.2-fold in Alpha convalescent

- 52 samples. Antigenic mapping reveals both Zeta and Omicron as separate antigenic clusters.
- 53 Double dose vaccination showed robust neutralization for Alpha, Beta, Gamma, Delta and Zeta, with
- 54 fold-change reduction of only 2.8 (for Alpha) up to 6.9 (for Beta). Escape from neutralization for Zeta
- 55 was largely restored in vaccinated individuals, while Omicron still showed a loss of neutralization of
- 56 85.7-fold compared to pre-VOC SARS-CoV-2.

57 Combined immunity from infection followed by vaccination or vaccine breakthrough infection showed 58 highest titers and most robust neutralization for heterologous variants. Breakthrough infection with Delta 59 showed only 12.5-fold reduced neutralization for Omicron, while breakthrough infection with Omicron 60 showed only a 1.5-fold loss for Delta, suggests that infection with antigenically different variants can 61 boost immunity for antigens closer to the vaccine strain. Antigenic cartography showed also a tendency 62 towards broader neutralizing capacity for heterologous variants.

We conclude that the complexity of background immunity needs to be taken into account when assessing new VOCs. Development towards separate serotypes such as Zeta was already observed before Omicron emergence, thus other factors than just immune escape must contribute to Omicrons rapid dominance. However, combined infection/vaccination immunity could ultimately lead to broad neutralizing capacity also against non-homologous variants.

68 Keywords

SARS-CoV-2, COVID19, variants of concern, Alpha, Beta, Gamma, Delta, Zeta, Omicron, PRNT,
 neutralization, vaccination

Introduction 71

72 In late 2019, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in Wuhan 73 (China) causing a pandemic that led to an unprecedented international health crisis of yet unknown 74 outcome [1, 2]. Shortly after its emergence, SARS-CoV-2 acquired the D614G mutation in the spike 75 protein in February 2020, which quickly replaced all other circulating variants and spread worldwide. 76 The evolutionary advantage of D614G is associated with enhanced binding to the human receptor and 77 increased replication and thus presumably better transmissibility [3]. After largely uncontrolled 78 transmission on a global scale during 2020, the emergence of the first variants of concern (VOCs) was 79 observed [4]. The VOCs consist of the Alpha variant, first detected in the UK; the Beta variant, first 80 detected in South Africa, the Gamma variant, first detected in South America, the Delta variant, first 81 detected in India and the Omicron variant, very recently reported from South Africa [5]. Variants of 82 concern were characterized by a rapid increase in case numbers and they quickly outcompeted earlier strains in their region of emergence. The latest emergence is the Omicron variant in late 2021 with the 83 84 so far highest number of mutations compared to earlier variants and the majority of them located in the 85 spike protein [4]. Thus, suspicion of escape from antibody responses derived from earlier variants and 86 vaccines by Omicron is high.

87 In addition to VOCs, other variants were identified that were of less concern and therefore classified as 88 variants of interest (VOI) due to aspects in their epidemiology or genetic signatures potentially leading 89 to an altered phenotype, among them the (former) VOI Zeta that arose in parallel with the Gamma 90 variant in South America at a time when a local surge in cases was observed but has disappeared in 91 the meantime [6-10].

92 Currently, few treatments are widely available for SARS-CoV-2 and mostly dedicated to risk groups, 93 therefore prevention and protection through vaccine-mediated immunity is still the proposed method for 94 ending the pandemic [11]. Depending on countries, medium to high levels of population immunity have 95 already been reached through vaccination or infection, but there are huge geographical differences 96 when it comes to the proportions of the population infected, different circulation of variants against which 97 immunity was obtained, percentage of vaccinated individuals, vaccine doses and type of vaccine used. 98 In light of that, it is of particular importance to evaluate the neutralizing potential of elicited antibodies 99 against clinical isolates of VOCs/VOIs to detect immune escape variants early and understand the 100 impact of such variants on the further course of the pandemic.

101 The mRNA-based vaccine Pfizer-BioNTech BNT162b2 encodes a stabilized full-length SARS-CoV-2 102 spike ectodomain derived from the Wuhan-Hu-1 genetic sequence and elicits potent neutralizing 103 antibodies [12], as does the mRNA-based vaccine Moderna mRNA-1273 [13]. However, emerging 104 SARS-CoV-2 variants include multiple substitutions and deletions in the major target of neutralizing antibodies, the spike glycoprotein, including the N-terminal (NTD) and the receptor-binding domains 105 106 (RBD), with the largest number of mutations of over 30 observed in the Omicron variant. This raises the 107 question of whether neutralizing antibodies induced by early circulating strains or by current vaccines 108 can effectively neutralize recently emerged virus variants. So far, studies indicated that mutations that 109 have been accumulating in the spike protein, especially in the RBD, are associated with increased 110 affinity to the human ACE2 receptor [14], as well as with resistance to neutralization from antibodies of

previously infected or vaccinated patients [15]. Mutations in the RBD pose the greatest risk for making SARS-CoV-2 more infectious and able to escape antibody neutralization [14]. Virus neutralizing antibody have been shown to be a correlate of protection from SARS-CoV-2 but more insights on neutralizing responses against emerging virus variants are needed [16-19].

115 In this study, we investigated the neutralizing potency of a panel of authentic sera or plasma from 116 individuals vaccinated twice with either BNT162b2 or mRNA-1273, and convalescent patients that had mild coronavirus disease 2019 (COVID-19). Patients were infected at different time points during the 117 118 pandemic with either an early-pandemic (pre-VOC) SARS-CoV-2 or one of the VOCs Alpha, Beta, Gamma, Delta or Omicron. We used authentic clinical isolates for pre-VOC SARS-CoV-2 (Pangolin 119 120 lineage B.1), Alpha, Beta, Gamma, Delta, Zeta and Omicron which were all isolated from patient samples collected from our routine diagnostic laboratory. We assessed the neutralizing potential 121 122 against homologous and heterologous variants by live virus plaque reduction neutralization test 123 (PRNT), widely regarded as the gold standard for the detection of SARS-CoV-2-specific neutralizing 124 antibodies [20].

125 Materials and Methods

126 Setting

127 The laboratory of virology of the University Hospital of Geneva is participating and coordinating the 128 SARS-CoV-2 variant and genomic surveillance funded by the Swiss Federal Office of Public Health

129 with constantly ongoing full genome sequencing of SARS-CoV-2 positive patient samples obtained

130 through the diagnostic unit of our Centre [21]. Up to around 400 positive patient specimens with a cycle

threshold (Ct) < 32 are sequenced each week since march 2021. From each variant that falls into any (Ct) = 130

132 of the categories of variant of concern/interest, at least one virus isolate is generated.

133 Patient samples

134 Convalescent sera or plasma during the early pandemic period (pre-VOC) were collected in the context 135 of two prospective cohort studies at the Geneva University Hospitals (HUG) and the Geneva Centre for 136 Emerging Viral Diseases (Understanding COVID study; ethics approval number: CCER 2020-00516, 137 Persistence study: ethics approval number: CCER 2020-00516). In addition, anonymized left-over 138 samples from apheresis collection of plasma (all collected in 2020) were available under the general 139 informed consent of the University Hospitals of Geneva.

Convalescent sera obtained from patients infected with a SARS-CoV-2 variant of concern (Alpha, Beta, 140 141 Gamma, Delta, Omicron) were collected in 2021 by contacting patients with confirmed SARS-CoV-2 142 infection for a blood collection in the convalescent period for the purpose of this study, same for vaccine 143 breakthrough infections (Ethics approval number: CCER 2020-02323). For each patient infected with a 144 variant, information on the infecting virus was available by full-genome sequence. No sequence information on the infecting strain was available from patients infected in 2020, however the first SARS-145 CoV-2 variant in Switzerland (Alpha) was only observed on Dec 24, 2020, and all pre-VOC samples 146 147 were collected before that date, thus they are considered pre-VOC. Plasma samples from vaccinated

- healthy individuals, vaccinated with 2 doses of BNT162b2 (Pfizer/BioNTech) or mRNA-1273 (Moderna)
- 149 vaccine at 28 days interval were available from a prospective observational study, collected 30 days
- after the 2nd dose (Ethics approval number: CCER ICOVax 2021-00430).
- 151 Convalescent samples were only collected from individuals with RT-PCR-confirmed diagnosis of SARS-
- 152 CoV-2 in our diagnostic unit, and sera/plasma were collected 3-137 days after diagnosis or symptom
- 153 onset (days post diagnosis, DPP). All vaccinated individuals were in addition tested for the presence of
- 154 nucleocapsid antibodies (Elecsys® Anti-SARS-CoV-2 anti-N) to screen for unrecognized infection prior
- to vaccination. There are no differences to be expected in the PRNT regarding the use of plasma or
- serum, therefore both sample types are used in parallel and termed "convalescent samples" throughout
- 157 the manuscript.

158 Viruses and cells.

Vero-E6 and Vero E6-TMPRSS cells were cultured in complete DMEM GlutaMax I medium supplemented with 10% fetal bovine serum, 1x Non-essential Amino Acids, and 1% antibiotics (Penicillin/Streptomycin) (all reagents from Gibco, USA). Vero-TMPRSS were kindly received from National Institute for Biological Standards and Controls (NIBSC, Cat. Nr. 100978).

163 All SARS-CoV-2 viruses used in this study were isolated from residual nasopharyngeal swabs collected 164 from patients presenting at the Geneva University Hospitals under general informed consent of the 165 hospital that allows usage of anonymized left-over materials. All patient specimens from which isolates were obtained were fully sequenced (Table S1). The following viruses were isolated as follows: B.1, 166 167 Alpha, Gamma and Zeta were isolated and propagated on Vero E6. The Beta variant isolate was 168 obtained as described previously [22]. Briefly, no primary Beta isolate could be obtained on VeroE6 but 169 only on A549 cells overexpressing human ACE2 [23]. Therefore, after primary isolation, A549-hACE2 170 cells were mixed with VeroE6 in a 1:1 ratio and inoculated with the passage 1 isolate. The next passage 171 was done on VeroE6 to generate the virus stock. The Omicron variant was primarily isolated on Vero-172 TMPRSS cells, then transferred to Vero E6 for generation of a virus stock. All virus stocks were titrated 173 on Vero-E6 cells and full genome sequenced. Sequences of initial patient specimens and virus isolates 174 obtained were compared for acquired mutations. Experiments with live infectious SARS-CoV-2 followed 175 the approved standard operating procedures of our biosafety level 3 facility (BSL-3).

176 Plaque Reduction Neutralization Test (PRNT).

177 Following the PRNT procedure, Vero-E6 cells were seeded at a density of 4x10⁵ cells/mL in 24-well cell 178 culture plates. A total of 34, 12, 8, 10 and 22 sera/plasma samples from patients infected with pre-VOC SARS-CoV-2, Alpha, Beta Gamma, Delta or sera from individuals vaccinated with BNT162b2/mRNA-179 180 1273, respectively, were used for determining the neutralizing titers against B.1 (first pandemic wave strain containing only the D614G substitution in the spike gene), Alpha, Beta, Gamma, Zeta, Delta and 181 182 Omicron variants as described earlier [24]. Briefly, all sera/plasma were heat-inactivated at 56°C for 30 min and serially diluted in Opti-Pro serum-free medium starting from 1:10 until up to 1:5120 if necessary. 183 184 Sera/plasma were mixed with 50PFU of variant isolates (B.1, Alpha, Beta, Gamma, Delta, Zeta and Omicron) and incubated at 37°C for 1h. All samples were run in duplicate and for each neutralization 185 186 experiment an infection control (no serum/plasma) and a reference serum were used to ensure

187 reproducibility between different experiments. Vero-E6 cells were washed 1x with PBS and inoculated 188 with the virus serum/plasma mixture for 1h. Afterwards, the inoculum was removed and 500uL of the 189 overlay medium also used for the plaque assays was added. After incubation for 3 days at 37°C, 5% 190 CO2, the overlay medium was removed, cells were fixed in 6% formaldehyde solution for at least 1h, 191 plates were washed 1x with PBS and stained with crystal violet. Plaques were counted in wells 192 inoculated with virus- serum/plasma mixtures and compared to plaque counts in infection control wells. The 90% reduction endpoint titers (PRNT₉₀) were calculated by fitting a 4-parameter logistics curve with 193 194 variable slope to the plaque counts of each serum/plasma using GraphPad Prism version 9.2.0. For 195 samples that did not reach 90% reduction at a 1:10 dilution, we extrapolated the titer until a dilution of 196 1, i.e. undiluted sample. If the extrapolation reached a titer below 1, the sample was given a value of 197 0.5 and considered negative.

198

199 Antigenic cartography

Antigenic maps were constructed with the software from https://acmacs-web.antigenic-cartography.org. The maps were generated with PRNT90 titers obtained for convalescence specimens from pre-VOC SARS-CoV-2, Alpha, Beta, Gamma and Delta and for post-vaccine specimens with and without prior infection, as described previously [25]. Breakthrough infections with Delta and Omicron were not included due to low number of samples.

205

206 Statistical analysis

Geometric means with 95% CI were used for comparison of PRNT₉₀ titers. All statistical analyses were
 conducted using GraphPad Prism version 9.1.0 software, performed using log10 ANOVA transformed
 PRNT₉₀ titers. Results were considered significant with p values <0.05.

210 Results

To evaluate the neutralization capacity of SARS-CoV-2 specific antibodies against SARS-CoV-2 variants (pre-VOC, Alpha, Beta, Gamma, Delta, Zeta and Omicron), a panel of convalescent blood specimens were used from i) individuals previously infected with pre-VOC SARS-CoV-2 (n=34), ii) individuals previously infected with VOCs Alpha (n=12), Beta (n=8), Gamma (n=10), Delta (n=10) iii) BNT162b2 or mRNA-1273 vaccinated individuals with (n=6) and without prior infection (n=16) iv) BNT162b2 or mRNA-1273 vaccinated individuals with a break-through infection with either Delta (n=4)

or Omicron (n=4) (**Table 1**).

218 Neutralizing capacity from infection-derived convalescent samples

Geometric mean PRNT₉₀ titers of convalescent specimens from individuals infected with pre-VOC SARS-CoV-2 were 37.3 (95%CI: 25.4-54.9) against B.1, 16.7 (95%CI: 9.7-28.8) against Alpha, 14.0 (95%CI: 8.8-22.3) against Beta, 10.3 (95%CI:6.4-16.6) against Gamma, 12.0 (95%CI:7.0-20.3) against Delta, 1.4 (95%CI: 0.9-2.4) against Zeta, and 0.8 (95%CI:0.6-1.2) against Omicron. Compared to B.1

for Zeta and 45.6 for Omicron (**Figure 1A**). None of the samples failed to neutralize the homologous virus. Only 1/34 (3%), 2/34 (6%), 3/34 (9%) and 3/34 (9%) failed to neutralize Alpha, Beta, Gamma and Delta, respectively, whereas 21/34 (62%) and 29/34 (85%) completely failed to neutralize the Zeta and Omicron variant.

For patients previously infected with the Alpha variant (n=12), geometric mean PRNT₉₀ titers were 45.5 (95%CI:34.3-60) for Alpha, 27.8 (95%CI:19.8-39.0) for B.1, 7.4 (95%CI:4.0-13.5) for Beta, 3.8 (95%CI:1.6-8.7) for Gamma, 5.9 (95%CI:2.8-12.2) for Delta, 1.6 (95%CI:0.7-3.6) for Zeta and 0.8 (95%CI:0.4-1.7) for Omicron. Compared to the homologous Alpha variant, this results in a reduction of 1.6 (B.1), 6.2 (Beta), 12.0 (Gamma), 7.7 (Delta), 28.2 (Zeta) and 56.1 (Omicron). Complete loss of neutralization was observed for 3/12 (25%) samples for Gamma, 1/12 (8%) for Delta, 5/12 (42%) for Zeta and 10/12 (83%) for Omicron (**Fig. 1B**).

235

For individuals previously infected with the Beta variant (n=8), geometric mean PRNT₉₀ titers were 20.6 (95%CI:6.8-62.6) for Beta, 6.0 (95%CI:1.3-27.2) for B.1, 2.6 (95%CI:0.4-14.9) for Alpha, 2.6 (95%CI:0.4-15.8) for Gamma, 3.2 (95%CI:0.7-15.3) for Delta, 1.7 (95%CI:0.4-7.5) for Zeta and 0.9 (95%CI:0.4-2.3) for Omicron. Compared to the homologous virus (Beta), this results in a fold-reduction of 3.5 for B.1, 8.0 for Alpha, 7.8 for Gamma, 6.4 for Delta, 12.4 for Zeta and 23.0 for Omicron. Complete loss of neutralization was observed for 1/8 (12.5) for B.1, 4/8 (50%) for Alpha, 4/8 (50%) for Gamma, 3/8 (37.5) for Delta, 4/8 (50%) for Zeta and 6/8 (75%) for Omicron (**Fig. 1C**).

243

For individuals previously infected with the Gamma variant (n=10), geometric mean PRNT₉₀ titers were 244 245 55.6 (95%CI:24.1-128) for Gamma, 20.5 (95%CI:7.6-55.5) for B.1, 13.9 (95%CI:5.9-32.9) for Alpha, 18.3 (95%CI:8.9-37.4) for Beta, 3.2 (95%CI:1.0-10.1) for Delta, 10.2 (95%CI:5.2-20.2) for Zeta and 2.1 246 247 (95%CI:0.7-6.4) for Omicron. Compared to the homologous virus, fold reduction in neutralization was 248 2.7 for B.1, 4.0 for Alpha, 3.0 for Beta, 17.6 for Delta, 5.4 for Zeta and 26.9 for Omicron. Complete loss 249 of neutralization was observed for 4/10 (40%) for Delta and 5/10 (50%) for Omicron (Fig. 1D). Of note, 250 a rather strong loss of neutralization in Gamma convalescent samples was observed for Delta, while 251 neutralization was less affected for the Zeta variant.

252

For individuals previously infected with Delta (n=10), geometric mean PRNT₉₀ titers were 72.8 (95%CI:33.9-156.2) for Delta, 25.1 (95%CI:14.0-45.1) for B.1, 18.4 (95%CI:9.5-35.4) for Alpha, 13.2 (95%CI:7.4-23.5) for Beta, 15.0 (95%CI:7.8-28.7) for Gamma, 10.4 (95%CI:4.0-26.9) for Zeta and 3.1 (95%CI:1.0-9.6) for Omicron. Fold reduction compared to homologous virus (Delta) was 2.9 for B.1, 4.0 for Alpha, 5.5 for Beta, 4.9 for Gamma, 7.0 for Zeta and 23.8 for Omicron. Complete loss of neutralization was 1/10 (10%) for Zeta and 4/10 (40%) for Omicron (**Fig. 1E**).

259

A heatmap for fold-change reduction of neutralization was generated to summarize findings across all convalescent specimens (**Fig. 1F**). Here, rather robust neutralization of pre-VOC convalescent specimens against VOCs Alpha, Beta, Gamma and Delta is visible while the other variants showed

stronger escape from immunity against heterologous variant. Immune escape properties for Zeta and Omicron are visible, with stronger immune escape of Zeta from pre-VOC and Alpha immunity, but less from Gamma and Delta immunity. Immune escape of Omicron was pronounced throughout all specimens, although the fold-change reduction is in a comparable range to that of Zeta for some combinations.

268 Neutralizing capacity from post-vaccine and combined post-vaccine/infection-derived samples

269 We investigated a total of 30 patient specimens from either double-vaccinated individuals (n=16) or with

270 combined vaccination-infection-derived immunity, either through prior infection followed by vaccination,

- 271 or vaccination followed by a vaccine breakthrough infection with Delta or Omicron (n=14).
- 272

273 In contrast to all infection-derived convalescent samples, geometric mean PRNT₉₀ titers were much 274 higher for individuals double-vaccinated with either BNT162b2 or mRNA-1273 with titers of 338.0 (95%CI:247.4-461.6) against B.1, 121.7 (95%CI:86.0-172.3) against Alpha, 49.3 (95%CI:28.1-86.8) for 275 276 Beta, 62.8 (95%CI:36.0-109.5) for Gamma, 95.6 (95%CI:69.4-131.7) for Delta, 78.5 (95%CI:50.4-277 122.5) for Zeta and 3.9 (95%Cl:1.8-8.7) for Omicron. This translates into a fold reduction of neutralization of 2.8 for Alpha, 6.9 for Beta, 5.4 for Gamma, 3.5 for Delta, 4.3 for Zeta and 85.7 for 278 279 Omicron. No complete loss of neutralization was seen for any VOC except Omicron in 5/16 (31%) 280 specimens (Fig. 2A).

281

Individuals with prior SARS-CoV-2 infection before double vaccination (n=6), as determined by presence of antibodies against the nucleocapsid, showed geometric mean PRNT₉₀ titers of 1190.4 (95%CI:837.8-1691) against B.1, followed by 683.2 (95%CI:516.3-904.1) for Alpha, 260.4 (95%CI:128.8-526.5) for Beta, 360.4 (95%CI:224.5-578.5) for Gamma, 494.1 (95%CI:419.4-582.1) for Delta, 351.8 (95%CI:227-545.2) for Zeta and 65.2 (95%CI:27.81-153.0) for Omicron. Fold reduction in neutralization was 1.7 for Alpha, 4.6 for Beta, 3.3 for Gamma, 2.4 for Delta, 3.4 for Zeta and 18.2 for Omicron. Of note, none of the specimens showed complete loss of neutralization (**Fig. 2B**).

289

290 In addition, we have investigated vaccinated individuals with a breakthrough infection with Delta (n=4) 291 and Omicron (n=4) for neutralization against both viruses which are currently the only VOCs co-292 circulating. For the first group, high geometric mean PRNT₉₀ titers of 1636 (95%CI: 128.2-20885) were 293 observed for the Delta while 130.9 (95%CI:24.9-688.9) was observed for Omicron. This results in a 294 12.5-fold reduction versus the homologous Delta, but no complete loss of neutralization was observed 295 (Fig. 2C). For Omicron breakthrough infections following vaccination, geometric mean PRNT₉₀ titers of 913.5 (95%CI:341.8-2442) were observed for Omicron, and 627.9 (95%CI:269.5-1463) were observed 296 297 for Delta, which equals a 1.5-fold loss of neutralization to heterologous Delta (Fig. 2 D). Highest titers 298 were seen against the infecting variant Omicron compared to Delta, although the prior vaccine-derived 299 immunity by an early pandemic spike is antigenically closer to Delta than to Omicron.

300

A heatmap of fold-change reduction of neutralization was performed to summarize findings across all post-vaccine and combined infection/vaccine specimens (**Fig. 2E**). The pronounced escape from vaccination specific for Omicron is visible here, while much less immune escape was observed for the other VOCs as well as for Zeta. Neutralization for Omicron is improved in all specimens with combined infection/vaccination immunity.

306

307 We also performed a mapping of our titration results using antigenic cartography (Fig. 3). Here we could 308 show that homologous sera cluster around the respective infecting virus, with Alpha and pre-VOC 309 specimens clustering together most closely. Earlier variants of concern before Omicron (Alpha, Beta, 310 Gamma, Delta) belong to one antigenic cluster. Zeta and Omicron are more distantly represented in the map with more than 3 units distance to all other viruses, thus presenting two separate antigenic 311 312 clusters (Fig. 3A). Post vaccine sera cluster around B.1 and Alpha strains, and a larger but equal 313 distance to Beta and Gamma is observed (Fig. 3B). Again, Zeta shows a larger antigenic distance, but 314 Omicron is the most distant. Of note, specimens with combined immunity from infection followed by 315 vaccination are located closer to the other non-Alpha VOCs compared to post-vaccination samples 316 without prior infection.

317

318 Individual profiles of SARS-CoV-2 homologous and heterologous neutralization

319

320 In addition to cumulated data (Fig. 1 and 2), neutralization profiles were also displayed on an individual 321 basis (Figure S1-S9). Here, inter-individual differences both in quantity of antibody response as well as 322 patterns of neutralization loss towards heterologous variants were observed, which does not 323 necessarily reflect pooled results in all individuals. For example, while neutralization against Omicron 324 was the lowest throughout convalescent samples, the differences between Alpha, Beta and Gamma 325 were less pronounced in some individuals. Of note, in all individual comparisons, the most efficient 326 neutralization was always observed against the homologous (infecting) strain through all convalescent sera as well as vaccine sera, when considering that the vaccine Spike most closely resembles the early 327 328 pandemic variant B.1.

329

330 Discussion

331 Here we assess neutralizing capacity towards seven SARS-CoV-2 variants by convalescent specimens

from individuals recovered from infection with the early-pandemic strain (pre-VOC) or the VOCs Alpha,

333 Beta, Gamma or Delta, from double-vaccinated individuals either with or without prior infection and from

double-vaccinated individuals infected with the Delta or Omicron variant.

We could show that highest SARS-CoV-2 neutralizing titers, either elicited through infection of vaccination, were always observed against the homologous strain (infecting strain or antigen used in the vaccine formulation), whereas a reduced neutralizing capacity was found for heterologous strains.

338 In agreement with our results, one study found lower neutralization for the Alpha and Gamma variant 339 by pre-VOC convalescent sera and lower neutralization for pre-VOC and Alpha in Gamma infected 340 patients, but reduced neutralization only for Gamma in vaccine sera [26]. In line with these 341 observations, Alpha-infected individuals showed reduced neutralization for the Beta variant [27]. 342 Reduction in neutralization capacity for the Delta variant was estimated between 4- and 8-fold in 343 vaccinated and 6-fold in convalescent sera [28]. Beyond our study, there is one pre-print that investigated the response to VOCs in a background of variant-specific convalescent samples from 344 345 individuals infected with pre-VOC, Alpha, Beta or Delta samples, that showed strongest neutralization 346 towards homologous vs heterologous virus for Alpha, Beta and Delta convalescent-variant pairs. [29]

347 We observed a reduction of neutralization capacity by first-wave SARS-CoV-2 convalescent and post-348 vaccine samples towards Alpha, Beta, Gamma and Delta to a comparable extent than what was 349 described by others [28, 30-33]. In comparison with neutralizing activity of other convalescent samples, 350 pre-VOC specimens induced immunity showed rather robust neutralization against Alpha, Beta, 351 Gamma and Delta, while convalescent specimens from VOC infections showed lower potential to 352 neutralize heterologous viruses. While for the Alpha variant, only slightly reduced neutralization was 353 described for both convalescent and vaccinee sera, a more pronounced reduction of neutralization was 354 observed for the Beta and Gamma variant [31, 32, 34-37]. Thus, Beta and Gamma comprised the two 355 VOCs with the most pronounced immune escape and at the same time successful enough to cause larger outbreaks in defined geographic region, without reaching global dominance in the time before 356 357 the emergence of Omicron. A recent study with pre-VOC SARS-CoV-2, Alpha and Beta in multiple 358 animal and cell culture models showed enhanced fitness of Alpha but not Beta which could be a reason 359 why Alpha but not Beta reached wide dominance in early 2021 [22].

360 Across our panel of convalescent and vaccine sera, the strongest decline of neutralization capacity was 361 observed for Zeta and Omicron. While convalescent specimens showed strong reduction of 362 neutralization for Zeta of up to 25.9-fold, neutralization capacity was restored in vaccinated individuals that showed only 4.3-fold decline compared to pre-VOC SARS-CoV-2. In contrast, for Omicron, a stark 363 364 loss of neutralizing activity of up to 46-fold or 86-fold was observed for both convalescent and vaccine 365 sera, respectively. Thus, fold-change reduction was even higher in vaccine sera than in convalescent 366 sera, although titer in vaccine sera were higher and therefore percentage of specimens with complete 367 loss was lower (31% of specimens vs. 83%). A similar loss of neutralization capacity against Omicron 368 was observed in other studies [29, 38-40], although no validation across the full range of VOC 369 convalescent sera was available before our data set. Interestingly, strongest loss of neutralization for 370 Zeta was in a similar range to the weakest loss of neutralization for Omicron, e.g. a 25.9-fold reduction 371 of Zeta in pre-VOC convalescent samples, and a 23.0-fold reduction of Omicron in Beta convalescent 372 samples. Such observed differences in fold-change reduction between Zeta and Omicron were less 373 than 2-fold in pre-VOC, Alpha and Beta convalescent sera, showing that even before the emergence 374 of Omicron, variants with strong immune escaping properties almost reaching that of Omicron were already circulating but did not become dominant. For post-Gamma and post-Delta specimens, the 375 376 differences between fold-change reduction of Zeta and Omicron were much bigger, with Omicron

377 showing a 3-5-fold higher escape of neutralization compared to Zeta. At least for Gamma, robust 378 neutralization for Zeta could be explained by a common origin as both are descendants from B.1.1.28 379 (Pango lineage) [10]. To the best of our knowledge, no data on neutralization of the Zeta variant by 380 convalescent or vaccinee samples has been described to date, and few other data were obtained on 381 this variant. Contrary, loss of neutralization for Delta was much more pronounced in Gamma than in 382 any other convalescent or vaccine sera with a 17.6-fold reduction. Such strong immune escape of Delta 383 in a variant-specific infection background has not been reported before.

384 A recent preprint mapped antigenic diversity of SARS-CoV-2, a method that was originally developed 385 to map antigenic relationship for influenza viruses by hemagglutinin inhibition assay [25, 41]. When 386 used to assess influenza viruses, one unit represents a 2-fold change in neutralization titer, and a 387 distance of more than 3 units is required for a separate an antigenic cluster, while below 3, it is 388 considered antigenically similar. They show that ancestral SARS-CoV-2, Alpha, Beta, Gamma and 389 Delta form one antigenic cluster, while Omicron forms a separate antigenic cluster. Differences to our study was that neutralization in this study was only done with a pseudovirus assay and with a lower 390 391 number of convalescent samples from patients infected with VOCs. Upon analysis for antigenic 392 cartography, our data confirm the findings of Omicron as another antigenic cluster by full virus PRNT, 393 but in addition for the first time we could also show Zeta forms a separate antigenic cluster [25]. 394 Furthermore, we can show that combined immunity after infection/vaccination shows a reduced 395 distance to heterologous variants such as Beta, Gamma and Delta in the map when compared to 396 vaccine samples without additional infection, indicative of broader neutralization.

397 Of note, we have observed large differences in the reduction of neutralization capacity across 398 specimens with different infection background which has not been described in this detail before. While 399 convalescent specimens of individuals infected with a pre-VOC SARS-CoV-2 and Alpha showed 45.6-400 and 56.1-fold reduction of neutralization capacity for Omicron, patients previously infected with the Beta, 401 Gamma or Delta variant showed a lower reduction in neutralization capacity of 23.0, 26.9 and 23.8-fold, 402 and a lower percentage of specimens with complete neutralization failure, respectively. These 403 differences could indicate that regional heterogeneity in background immunity could potentially 404 influence emergence and spread of Omicron or other future variants with immune escape properties.

405 A gradient of immune escape can be described from the variants investigated here, from pre-VOC to 406 Alpha (only slight immune escape, but successfully outcompeted earlier strains), Beta and Gamma 407 (more pronounced immune escape with regionally pronounced circulation but no global dominance) to 408 Zeta (variant with one of the strongest escapes of immunity prior to Omicron, but limited transmission). 409 Our data on Zeta, along with data two other VOIs Mu and Lambda, have shown the strongest escape 410 from neutralization in pandemic period before the emergence of Omicron [42-45]. Although differences 411 between escape from neutralization between Zeta and Omicron are only two-fold in some subgroups, 412 neutralization for Zeta was restored in vaccinee specimens, while this was not the case for Omicron. 413 This could hint towards different mechanisms of immune escape between SARS-CoV-2 variants, and 414 other fitness advantaged for Omicron beyond immune escape.

415 Of note, a mutation of position 484 in the receptor binding domain is found in Beta, Gamma, Zeta 416 (E484K) and Omicron (E484A). The same mutation arose independently also in a lineage of the Alpha 417 variant where it was also associated with escape from neutralizing antibodies [46]. It has been shown 418 that a mutation at position 484 of the spike tends to have the strongest effect on receptor binding and 419 neutralization [47-50]. While the mutation can explain, at least partly, the strong escape from 420 neutralization in Omicron, it has no or only very low influence on ACE2-binding and is therefore most 421 likely not associated with higher transmissibility, although the mechanism of transmissibility in Omicron 422 is not well understood [51].

423 We have shown that Omicron exhibits a strong escape from neutralization in both convalescent and 424 vaccine sera, although differences in fold change reduction exist depending on prior infection 425 background. However, it has been shown that a third dose of a mRNA vaccine is able to restore 426 neutralizing capacity [52-55]. Similarly, individuals with mixed immunity, i.e. infection prior to double 427 vaccination, or infection after double vaccination, also leads to higher neutralizing capacity towards 428 Omicron [29, 40]. With an increasing number of vaccine breakthrough infections observed during the 429 Delta wave and reports of a large number of vaccine breakthrough infections with Omicron, an 430 assessment of mixed immunity is of huge interest, especially for protection against new variants [56]. 431 In addition, it has been speculated whether the immune response towards an antigenically drifted 432 SARS-CoV-2 variant will be influenced by pre-existing immunity [57].

433 Here we investigated four individuals with a Delta breakthrough infection after double vaccination and 434 have found high neutralizing titers for Delta. Neutralization capacity for Omicron was markedly reduced, 435 but titers were still higher than titers against other VOCs in double-vaccinated individuals indicating that 436 even a boost with a mismatched strain (Delta) can lead to a considerable increase in immunity against 437 Omicron. Similarly, vaccine breakthrough infections with Omicron resulted in very high neutralization 438 titers against the Omicron variant indicating that infection with an antigenically drifted variant led to a robust Omicron-specific immune response despite the presence of pre-existing immunity against the 439 440 original pandemic strain. Interestingly, neutralizing titers against the Delta variant were only minimally 441 reduced compared to Omicron indicating that infection with antigenically different variants can boost 442 immunity against variants that are antigenically similar to the vaccine strain.

443 Population immunity and evolutionary pressure might differ on a regional scale depending on the 444 immunity induced by earlier circulating variants [58]. High titers of neutralizing antibodies, such as elicited by the vaccine, were at least partially able to neutralize earlier variants before the rise of 445 446 Omicron. From an epidemiological point of view, this highlights that vaccine-induced immunity probably 447 would have allowed lower virus circulation compared to immunity induced through infections, which 448 may have prevented the evolution of new variants that harbor immune escape properties such as 449 Omicron. Although the origin of Omicron is not well understood, it was speculated that a high background of Beta-variant immunity has favored the development of Omicrons immune escaping 450 451 properties [59]. In contrast to earlier variants, Omicron is showing a rapid increase in cases with a short doubling time, in addition to its immune-escaping properties [60]. This, together with reduced 452

453 neutralization is also suggestive of decreased vaccine effectiveness, will further complicate the454 management of the pandemic.

455 Limitations of our study are the relatively low number of specimens that were available for convalescent specimens of patients previously infected with variants. Furthermore, we cannot exclude, that 456 457 individuals infected with a VOC have not already been infected in 2020 with a first-wave virus and thus antibodies are derived from multiple infections with more than one variant. In addition, the Beta variant, 458 459 which could not be readily isolated on VeroE6 cell lines had to be adapted to VeroE6 in order to be 460 usable for our PRNT, thus the isolate accumulated mutations, which could affect the neutralization 461 results. No convalescent samples were available from individuals infected with Zeta, and no 462 convalescent samples were yet available from individuals infected with Omicron without prior 463 vaccination. Furthermore, testing of single time points after infection/vaccination can only provide a 464 snapshot and not inform on the duration of antibody responses over time. All our blood specimens were 465 collected at rather early time points after infection or vaccination, thus with time, a broader neutralizing capacity towards the heterologous variant might be observed due to somatic hypermutation and affinity 466 467 maturation, although in the case of Omicron most likely will not restore neutralization loss [61].

468 Overall, we could show that responses to variants before Omicron were associated with reduced, but 469 not complete loss in neutralization both by infection-derived as well as vaccine derived immunity, 470 although variants such as Zeta have already shown immune escape properties, but did not become 471 dominant at the time of their emergence. Omicron, in contrast to earlier variants displays a strong 472 immune escape with a surge in case numbers in many areas of the world. Furthermore, the continuous 473 emergence of SARS-CoV-2 variants since late 2020 shows that the virus is still underlies evolutionary 474 pressure and currently available vaccines might not be sufficient to mitigate the pandemic in the near-475 term future. Furthermore, whether immunity of a population was obtained by a vaccine or by previous 476 infection with a certain SARS-CoV-2 variants could influence the type of evolutionary pressure for 477 circulating SARS-CoV-2 and lead to the emergence of new variants that differ for countries with major 478 vaccine vs. major infection-derived immunity.

479

480 Acknowledgments

We thank Pascale Sattonnet-Roche for excellent technical help. We thank the staff of the laboratory of virology at the HUG for support. We thank all clinicians and technical staff responsible of the different clinical cohorts for their help. We are grateful for the patients who were willing to donate their samples and agree to participate in our research.

We thank Samuel Cordey and Florian Laubscher for help with sequence analysis. We thank Mirco
Schmolke and Beryl Mazel-Sanchez for A549-hACE2 cells.

487 We thank Volker Thiel, Jenna Kelly and Silvio Steiner, Vetsuisse Bern, for help with Omicron 488 sequencing.

489 Funding

- 490 This work was supported by the Swiss National Science Foundation 196644, 196383, NRP (National
- 491 Research Program) 78 Covid-19 Grant 198412, the Fondation Ancrage Bienfaisance du Groupe Pictet
- 492 and the Fondation Privée des Hôpitaux Universitaires de Genève.

Convalescent cohort									
Infecting virus	Number patient	Gender (M/F)	Age, mean	DPP/DPOS	Sample type	Infection period			
pre-VOCs	34	20/14	31	32 (25-37)*	Serum, Plasma	March-June 2020			
Alpha	12	8/4	51	27 (8-42)	Serum	December 2020-February 2021			
Beta	8	2/6	42	50 (3-98)	Serum	January-May 2021			
Gamma	10	4/6	44	54 (7-137)	Serum	January-April 2021			
Delta	10	4/6	42	71 (9-118)	Serum	May-July 2021			
Vaccinated cohort		1	I		1				
Vaccine	Number of patient	Gender (M/F)	Age mean	WPV Mean weeks (range)	Sample type	Date of vaccination			
mRNA vaccine	16	4/12	52	8	Serum, Plasma	March-May 2021			
Vaccinated and infected individuals									
Vaccination/infection status	ccination/infection statusNumber of patientGender (M/F)Age meanWPV MeanSampleveeks (range)type		Intervall vaccination – infection Mean weeks (range)						
Prior infection + 2x vaccination	6	3/3	46	n.a	Serum	n.a.			
2x vaccination + breakthrough (Delta)	4	2/2	42	28 (16-37)	Serum	20 (11-28)			
2x vaccination + breakthrough (Omicron)	2	1/1	49	26 (24-28)	Serum	23 (21-25)			
1x vaccination + breakthrough (Omicron)	2	2/0	13	5 (5-5)	Serum	3 (3)			

Table 1. Characteristic of sample cohorts used in this study. DPP, days post diagnosis, DPOS, days post symptom onset (marked with *) WPV, weeks post

494 2nd dose vaccination, n.a. not accessible

495 Figures



496

497 Figure 1. Neutralization in infection-derived blood specimens against seven authentic isolates of SARS-498 CoV-2 variants (B.1, Alpha, Beta Gamma, Delta, Zeta, Omicron). Bars represent geometric mean titers 499 (GMT) of 90% reduction endpoint titers (PRNT₉₀) with 95% confidence interval. Convalescent 500 specimens are derived from individuals infected with (A) early-pandemic SARS-CoV-2 (pre-VOC), (B) 501 Alpha (C) Beta (D) Gamma (E) Delta. Colored numbers above bars refer to fold change reduction of 502 GMT versus the homologous (infecting) variant, shown as first bar of each figure. Colored numbers 503 below each bar represents number of specimens with complete loss of neutralization (PRNT₉₀ titer < 1). *p < 0.05, **p < 0.003, ***p < 0.0002 and ****p < 0.0001 (**F**) Heatmap of fold-reduction in neutralization 504 505 based on PRNT₉₀ data from A-E.

506



507

Figure 2. Neutralization in infection-derived blood specimens against seven authentic isolates of SARS-508 CoV-2 variants (B.1, Alpha, Beta Gamma, Delta, Zeta, Omicron). Bars represent geometric mean titers 509 510 (GMT) of 90% reduction endpoint titers (PRNT₉₀) with 95% confidence interval. Cohorts consist of 511 individuals with (A) double-dose mRNA vaccination, (B) prior SARS-CoV-2 infection followed by 512 double-dose mRNA vaccination (C) Delta breakthrough infection of double-vaccinated individuals and (D) Omicron breakthrough infection following double (n=2) and single (n=2) mRNA vaccination. Colored 513 514 numbers above bars refer to fold change reduction of GMT versus the homologous (infecting) variant, shown as first bar of each figure. Colored numbers below each bar represents number of specimens 515 516 with complete loss of neutralization (PRNT₉₀ titer < 1). *p < 0.05, **p < 0.003, ***p<0.0002 and 517 ****p < 0.0001 (**F**) Heatmap of fold-reduction in neutralization based on PRNT₉₀ data from A-D.



519 Figure 3. Mapping of antigenic relationship using antigenic cartography for (A) convalescent specimens

- 520 from pre-VOC SARS-CoV-2, Alpha, Beta, Gamma and Delta infections and (B) all convalescent and
- 521 post-vaccination specimens with and without prior infection. For graphical reasons only post vaccination
- 522 specimens are shown in (**B**)

523

518

medRxiv preprint doi: https://doi.org/10.1101/2021.12.28.21268491; this version posted January 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

524 References

- 525 1. Zhu, N., et al., A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med, 526 2020. 382(8): p. 727-733.
- 527 Zhou, P., et al., A pneumonia outbreak associated with a new coronavirus of probable bat 2. 528 origin. Nature, 2020. 579(7798): p. 270-273.
- 529 3. Zhou, B., et al., SARS-CoV-2 spike D614G change enhances replication and transmission. 530 Nature, 2021. 592(7852): p. 122-127.
- 531 (WHO) 4. World Health Organization 08.12.2021]; Available from: 532 https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.
- 533 Viana, R., et al., Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern 5. 534 Africa. medRxiv, 2021: p. 2021.12.19.21268028.
- 535 6. Tegally, H., et al., Detection of a SARS-CoV-2 variant of concern in South Africa. Nature, 2021. 536 **592**(7854): p. 438-443.
- 537 7. Davies, N.G., et al., Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in 538 England. Science, 2021. 372(6538).
- 539 8. Campbell, F., et al., Increased transmissibility and global spread of SARS-CoV-2 variants of 540 concern as at June 2021. Euro Surveill, 2021. 26(24).
- 541 9. Faria, N.R., et al., Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. 542 Science, 2021. 372(6544): p. 815-821.
- 543 10. Voloch, C.M., et al., Genomic characterization of a novel SARS-CoV-2 lineage from Rio de 544 Janeiro, Brazil. J Virol, 2021.
- 545 11. NIH. 08.12.2021]; Available from: https://www.covid19treatmentguidelines.nih.gov.
- Walsh, E.E., et al., Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. 546 12. 547 N Engl J Med, 2020. 383(25): p. 2439-2450.
- 548 13. Jackson, L.A., et al., An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med, 549 2020. 383(20): p. 1920-1931.
- 550 Wang, R., et al., Vaccine-escape and fast-growing mutations in the United Kingdom, the United 14. 551 States, Singapore, Spain, India, and other COVID-19-devastated countries. Genomics, 2021. **113**(4): p. 2158-2170. 552
- 553 Hoffmann, M., et al., SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. 15. 554 Cell, 2021. 184(9): p. 2384-2393 e12.
- 555 16. Addetia, A., et al., Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. J Clin Microbiol, 2020. 556 557 58(11).
- 558 Khoury, D.S., et al., Neutralizing antibody levels are highly predictive of immune protection 17. 559 from symptomatic SARS-CoV-2 infection. Nat Med, 2021. 27(7): p. 1205-1211.
- Earle, K.A., et al., Evidence for antibody as a protective correlate for COVID-19 vaccines. 560 18. Vaccine, 2021. 39(32): p. 4423-4428. 561
- 562 19. Huang, A.T., et al., A systematic review of antibody mediated immunity to coronaviruses: 563 antibody kinetics, correlates of protection, and association of antibody responses with severity 564 of disease. medRxiv, 2020.
- 565 20. Chmielewska, A.M., et al., Immune response against SARS-CoV-2 variants: the role of neutralization assays. NPJ Vaccines, 2021. 6(1): p. 142. 566
- Health 567 21. Federal Office for Public Switzerland 08.12.2021]; Available from: 568 https://www.bag.admin.ch/bag/en/home/das-bag/aktuell/medienmitteilungen.msg-id-569 83732.html.
- 570 22. Ulrich, L., et al., Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta. Nature, 571 2021.
- 572 Ilmjarv, S., et al., Concurrent mutations in RNA-dependent RNA polymerase and spike protein 23. 573 emerged as the epidemiologically most successful SARS-CoV-2 variant. Sci Rep, 2021. 11(1): p. 574 13705.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.28.21268491; this version posted January 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Meyer, B., et al., Validation of a commercially available SARS-CoV-2 serological immunoassay. 575 24. 576 Clin Microbiol Infect, 2020. 26(10): p. 1386-1394. 577 van der Straten, K., et al., Mapping the antigenic diversification of SARS-CoV-2. medRxiv, 2022: 25. 578 p. 2022.01.03.21268582. 579 Gidari, A., et al., Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, 26. 580 convalescent and P.1 infected. J Infect, 2021. 83(4): p. 467-472. 581 27. Faulkner, N., et al., Reduced antibody cross-reactivity following infection with B.1.1.7 than with 582 parental SARS-CoV-2 strains. Elife, 2021. 10. 583 Davis, C., et al., Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern 28. 584 following vaccination. PLoS Pathog, 2021. 17(12): p. e1010022. 585 29. Rössler, A., et al., SARS-CoV-2 B.1.1.529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent individuals. medRxiv, 2021: p. 2021.12.08.21267491. 586 587 Hojjat Jodaylami, M., et al., Cross-reactivity of antibodies from non-hospitalized COVID-19 30. 588 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins. 589 Sci Rep, 2021. 11(1): p. 21601. 590 31. Muik, A., et al., Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 591 vaccine-elicited human sera. Science, 2021. 371(6534): p. 1152-1153. 592 32. Shen, X., et al., Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351. N Engl J Med, 2021. 593 **384**(24): p. 2352-2354. 594 Mlcochova, P., et al., SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. 33. 595 Nature, 2021. 599(7883): p. 114-119. 596 34. Edara, V.V., et al., Infection- and vaccine-induced antibody binding and neutralization of the 597 B.1.351 SARS-CoV-2 variant. Cell Host Microbe, 2021. 29(4): p. 516-521 e3. 598 35. Skelly, D.T., et al., Two doses of SARS-CoV-2 vaccination induce robust immune responses to 599 emerging SARS-CoV-2 variants of concern. Nat Commun, 2021. 12(1): p. 5061. 600 36. Wang, P., et al., Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell 601 Host Microbe, 2021. 29(5): p. 747-751 e4. 602 37. Bates, T.A., et al., Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine 603 Immune Serum Samples. JAMA, 2021. 604 38. Dejnirattisai, W., et al., Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by 605 post-immunisation serum. medRxiv, 2021: p. 2021.12.10.21267534. 606 Cele, S., et al., SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 39. 607 elicited neutralization and requires ACE2 for infection. medRxiv, 2021: р. 608 2021.12.08.21267417. 609 40. Wilhelm, A., et al., Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera 610 and monoclonal antibodies. medRxiv, 2021: p. 2021.12.07.21267432. Smith, D.J., et al., Mapping the antigenic and genetic evolution of influenza virus. Science, 611 41. 612 2004. 305(5682): p. 371-6. 613 42. Acevedo, M.L., et al., Infectivity and immune escape of the new SARS-CoV-2 variant of interest 614 Lambda. medRxiv, 2021: p. 2021.06.28.21259673. 615 43. Xie, X., et al., Emerging SARS-CoV-2 B.1.621/Mu variant is prominently resistant to inactivated 616 vaccine-elicited antibodies. Zool Res, 2021. 42(6): p. 789-791. 617 44. Uriu, K., et al., Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine 618 Serum. N Engl J Med, 2021. 385(25): p. 2397-2399. 619 45. Liu, H., et al., The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to 620 escape vaccines. bioRxiv, 2021. 621 46. Collier, D.A., et al., Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature, 2021. 593(7857): p. 136-141. 622 623 47. Greaney, A.J., et al., Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding 624 domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe, 625 2021. **29**(3): p. 463-476 e6.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.28.21268491; this version posted January 12, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

- 626 48. Andreano, E., et al., SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 627 convalescent plasma. bioRxiv, 2020.
- 628 49. Liu, Z., et al., Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that 629 attenuate monoclonal and serum antibody neutralization. bioRxiv, 2021.
- 630 50. Weisblum, Y., et al., Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. 631 Elife, 2020. 9.
- 632 51. Starr, T.N., et al., Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. Cell, 2020. 182(5): p. 1295-1310 e20. 633
- 634 Garcia-Beltran, W.F., et al., mRNA-based COVID-19 vaccine boosters induce neutralizing 52. *immunity against SARS-CoV-2 Omicron variant.* medRxiv, 2021. 635
- 636 53. Doria-Rose, N.A., et al., Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape 637 from Neutralizing Antibodies. medRxiv, 2021.
- Nemet, I., et al., Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. 638 54. 639 medRxiv, 2021: p. 2021.12.13.21267670.
- 640 55. Yu, X., et al., Enhanced neutralization against SARS-CoV-2 by vaccine booster exhibits 641 reduction of Omicron variant. medRxiv, 2021: p. 2021.12.17.21267961.
- 642 56. Eggink, D., et al., Increased risk of infection with SARS-CoV-2 Omicron compared to Delta in 643 vaccinated and previously infected individuals, the Netherlands, 22 November to 19 December 644 2021. medRxiv, 2021: p. 2021.12.20.21268121.
- 645 57. Brown, E.L. and H.T. Essigmann, Original Antigenic Sin: the Downside of Immunological 646 Memory and Implications for COVID-19. mSphere, 2021. 6(2).
- Karuna, S., et al., Neutralizing antibody responses over time in demographically and clinically 647 58. 648 diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A 649 cohort study. PLoS Med, 2021. 18(12): p. e1003868.
- 650 59. Zahradnik, J., et al., Receptor binding and escape from Beta antibody responses drive Omicron-651 B.1.1.529 evolution. bioRxiv, 2021: p. 2021.12.03.471045.
- 652 60. Yang, W. and J. Shaman, SARS-CoV-2 transmission dynamics in South Africa and 653 epidemiological characteristics of the Omicron variant. medRxiv, 2021: p. 654 2021.12.19.21268073.
- 655 61. Gaebler, C., et al., Evolution of antibody immunity to SARS-CoV-2. Nature, 2021. 591(7851): p. 656 639-644.

657 Supplementary data

- **Table S1.** Patient sample information from which virus isolates used in this study were obtained.
- Figure S1. Neutralizing antibody titers of each pre-VOC convalescent individual (P=plasma sample, S=
 serum sample).
- 661 **Figure S2.** Neutralizing antibody titers of each Alpha convalescent individual (S= serum sample).
- 662 **Figure S3.** Neutralizing antibody titers of each Beta convalescent individual (S= serum sample).
- 663 **Figure S4.** Neutralizing antibody titers of each Gamma convalescent individual (S= serum sample).
- 664 **Figure S5**. Neutralizing antibody titers of each Delta convalescent individual (S= serum sample).
- Figure S6. Neutralizing antibody titers of each post-vaccination individual with double vaccination)
 (P=plasma sample, S= serum sample).
- Figure S7. Neutralizing antibody titers of each post-vaccination individual with prior infection followed
 by double vaccination (P=plasma sample).
- Figure S8. Neutralizing antibody titers of each post-vaccination individual with Delta breakthroughinfection (S= serum sample).
- Figure S9. Neutralizing antibody titers of each post-vaccination individual with Omicron breakthroughinfection (S= serum sample).
- 673
- 674

	B.1	Alpha	Beta	Gamma	Delta	Zeta	Omicron
Name	hCoV- 19/Switzerland/GE- SNRCI-29943121/2020	hCoV- 19/Switzerland/201221 2272/2020	hCoV-19/Switzerland/GE- 33128281/2021	hCoV- 19/Switzerland/GE- 33115015/2021	hCoV-19/Switzerland/GE- 33896105/2021	hCoV-19/Switzerland/GE- 32966260/2021	hCoV-19/Switzerland/VD- HUG-36221084/2021
GISAID accession ID	EPI_ISL_414019	EPI_ISL_2131446	EPI_ISL_981782	EPI_ISL_981707	EPI_ISL_1811202	EPI_ISL_897700	EPI_ISL_7605546
Clade	G	GRY	GH	GR	GK	G	GRA
Pango lineage	B.1	B.1.1.7	B.1.351	P.1	AY.122	P.2	BA.1

Table S1. Patient sample information from which virus isolates were obtained









P8

S47











Figure S1.





Figure S2.







S72

Beta-Gamma-Delta-Zeta-Omicron-

0.1

Alpha

B.1

Beta-Gamma-Delta-

Zeta-Omicron-

100-

10

0.1

Alpha

B.1



















0.1

Alpha-

B.1-Beta-Gamma-Delta-Zeta-Omicron-





S108

















Figure S5.







0.1

Delta-B.1-B.1-Alpha-Beta-Gamma-Zeta-Omicron-



0.1

Delta – B.1 – Alpha – Beta – Gamma – Zeta – Omicron –

S125

Figure S6.













P100













1000

100

10

0.1

PRNT₉₀ titer



Figure S6.







Omicron-







